News | December 07, 2025
Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Relmada expects to initiate its Phase 3 program in the first half of 2026
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Subscribe To Our Newsletter & Stay Updated
